Pharma BD Deal Intelligence

Servier / Owkin, Inc.

2026 · Licensing/Option · Complete

Owkin licensed K Pro, its AI Scientist platform, together with multimodal patient data from its MOSAIC network, to Servier to advance the group's oncology research. Servier research teams gain access to MOSAIC multimodal patient data for analysis within K Pro, which supports molecule optimisation, target discovery, biomarker identification, subgroup optimisation and clinical trial design. The agreement extends a prior Owkin-Servier collaboration on patient subgroup identification in oncology. Financial terms were not disclosed.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2026 deals  ·  Servier deals